Viewing Study NCT00083720


Ignite Creation Date: 2025-12-25 @ 4:07 AM
Ignite Modification Date: 2025-12-26 @ 3:04 AM
Study NCT ID: NCT00083720
Status: COMPLETED
Last Update Posted: 2011-05-25
First Post: 2004-05-28
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
Sponsor: Eli Lilly and Company
Organization: